Similarly, elevated lipoic acid synthase (LIAS) expression predicts improved clinical outcomes in breast cancer, and upregulated expression of dihydrolipoamide S-acetyltransferase (DLAT) predicts poor prognosis in hepatocellular carcinoma 10, 11. This evidence concerns the gene LIAS and breast carcinoma.